Literature DB >> 15152700

Why don't Americans use cost-effectiveness analysis?

Peter J Neumann1.   

Abstract

Cost-effectiveness analysis (CEA) offers decision makers a structured, rational approach with which to improve the return on resources expended. But decades after its widespread promotion to the medical community, policy makers in the United States remain reluctant to use the approach formally. Indeed, the resistance to economic evidence in the United States in an era of evidence-based medicine in healthcare is perhaps the most notable development of all. This paper examines the resistance to CEA in the United States and explores ways in which to advance the field.

Mesh:

Year:  2004        PMID: 15152700

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  26 in total

1.  Reevaluating the benefits of folic acid fortification in the United States: economic analysis, regulation, and public health.

Authors:  Scott D Grosse; Norman J Waitzman; Patrick S Romano; Joseph Mulinare
Journal:  Am J Public Health       Date:  2005-09-29       Impact factor: 9.308

2.  Incorporating quality of evidence into decision analytic modeling.

Authors:  R Scott Braithwaite; Mark S Roberts; Amy C Justice
Journal:  Ann Intern Med       Date:  2007-01-16       Impact factor: 25.391

3.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  Evaluating health care programs by combining cost with quality of life measures: a case study comparing capitation and fee for service.

Authors:  Richard Grieve; Jasjeet S Sekhon; Teh-Wei Hu; Joan R Bloom
Journal:  Health Serv Res       Date:  2008-03-17       Impact factor: 3.402

5.  Waste in the U.S. Health care system: a conceptual framework.

Authors:  Tanya G K Bentley; Rachel M Effros; Kartika Palar; Emmett B Keeler
Journal:  Milbank Q       Date:  2008-12       Impact factor: 4.911

6.  Patient access to pharmaceuticals: an international comparison.

Authors:  Joshua Cohen; Laura Faden; Susan Predaris; Brian Young
Journal:  Eur J Health Econ       Date:  2007-02-06

7.  Economic evaluation and cost-effectiveness thresholds: signals to firms and implications for R & D investment and innovation.

Authors:  John A Vernon; Robert Goldberg; Joseph Golec
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

8.  Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions.

Authors:  O Alagoz; D Durham; K Kasirajan
Journal:  Pharmacogenomics J       Date:  2015-05-19       Impact factor: 3.550

9.  Cost-effectiveness of lung volume reduction surgery.

Authors:  Scott D Ramsey; Sean D Sullivan; Robert M Kaplan
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

10.  The role of economic evaluation in the decision-making process of family physicians: design and methods of a qualitative embedded multiple-case study.

Authors:  Chantale Lessard; André-Pierre Contandriopoulos; Marie-Dominique Beaulieu
Journal:  BMC Fam Pract       Date:  2009-02-11       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.